XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.95
-0.52 (-3.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.47
Open14.27
Bid13.10 x 4000
Ask18.00 x 3000
Day's Range13.39 - 14.79
52 Week Range10.26 - 20.16
Volume2,102,335
Avg. Volume1,335,743
Market Cap1.911B
Beta (3Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire4 days ago

    Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes

    OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...

  • PR Newswire4 days ago

    Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes

    OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...

  • GlobeNewswire5 days ago

    AquaBounty receives construction loan to support development efforts at its Rollo Bay property

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces that the Company’s Canadian subsidiary has received a construction loan in the amount of CA$2.0 million (US$1.6 million) from the Department of Economic Development of the Province of Prince Edward Island.  The proceeds of the loan will be used to complete construction of the Company’s 250-metric ton production facility on its Rollo Bay site. The Rollo Bay site, which includes an R&D hatchery, is currently undergoing construction of a 250-metric ton production facility and a broodstock facility.  Once complete, 20-30 technical jobs are expected to be added to AquaBounty’s operation.

  • GlobeNewswire5 days ago

    INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders

    NEW YORK, Oct. 16, 2018 -- Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies..

  • GlobeNewswire9 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or the “Company”) (NASDAQ: XON).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, Intrexon’s share price fell $0.34 per share, or 2.21%, to close at $15.05 per share on August 10, 2018.  Then, on August 13, 2018, Intrexon filed an amended and restated 10-Q for the quarter ended March 31, 2018.  On this news, Intrexon’s share price fell $0.95 per share, or 6.31%, to close at $14.10 per share on August 13, 2018.

  • GlobeNewswire13 days ago

    Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

    Ziopharm to Host Conference Call at 8 a.m. Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. With this exclusive license, Ziopharm now has full developmental control and exclusivity utilizing SB for TCRs targeted towards neoantigens and public antigens.

  • ACCESSWIRE18 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • ACCESSWIRE25 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • ACCESSWIRE27 days ago

    Today’s Research Reports on Stocks to Watch: Intrexon and Tilray

    NEW YORK, NY / ACCESSWIRE / September 25, 2018 / While one marijuana stock saw big gains on Monday another one came crashing down. Tilray saw big losses again on Monday despite a positive announcement. ...

  • GlobeNewswire27 days ago

    Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • ACCESSWIRE27 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • PR Newswire28 days ago

    Intrexon Announces Advances in Production of Medical Cannabis

    BUDAPEST, Hungary, Sept. 24, 2018 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced advances in the development of its microbial platform to produce cannabinoids for medical uses.  Through Intrexon's proprietary technologies, the Company has engineered a yeast strain to produce low-cost, robust and consistent cannabinoid outputs via fermentation.  This process utilizing microbes has potential to provide greater supply-chain security, and avoids the resource-intensive isolation that often leads to quality and quantity variability in end products. Further, this versatile strain was designed to enable the production of cannabinoids that only are produced today in miniscule amounts in cannabis plants as well as novel cannabinoids.  The Company has scaled the process and achieved titers approaching commercially relevant targets with anticipated production of pure cannabinoids at COGS $1,000/kg.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON). Such ...

  • PR Newswirelast month

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON)

    NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intrexon Corporation ("Intrexon" ...

  • PR Newswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK , Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON).   Such investors ...

  • Business Wirelast month

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intrexon Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or “the Company”) (NYSE: XON) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Intrexon filed a Form 8-K with the SEC on August 9, 2018, announcement that the Company would restate its unaudited interim consolidated financial statements for the quarter ended March 31, 2018.

  • Business Wirelast month

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intrexon Corporation – XON

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Intrexon Corporation

    NEW YORK, Sept. 13, 2018-- Levi & Korsinsky announces it has commenced an investigation of Intrexon Corporation concerning possible violations of federal securities laws.. On August 9, 2018, Intrexon filed ...

  • PR Newswirelast month

    Intrexon Announces Transfer of Stock Listing to Nasdaq

    Ticker symbol to remain "XON" GERMANTOWN, Md. , Sept. 12, 2018 /PRNewswire/ --  Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality ...

  • Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets
    PR Newswirelast month

    Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets

    YELLOW SPRINGS, Ohio, Sept. 10, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has recommended amendment of the Association of American Feed Control Officials (AAFCO) ingredient definition of dried black soldier fly larvae (BSFL) to include feeding to poultry.  The approval of BSFL for use in poultry feed expands the potential for this ingredient as a more sustainable source of protein and enables a nutritious, natural feed ingredient for poultry diets.

  • GlobeNewswire2 months ago

    CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    In a release issued earlier today by Ziopharm Oncology, Inc. (ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued. Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 18. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 8. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • GlobeNewswire2 months ago

    Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Omeros and Intrexon

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...

  • PR Newswire2 months ago

    Intrexon Business Update and Conference Call

    The Company is not announcing final financial results for the quarter ended June 30, 2018 and is delaying the filing of its quarterly report on Form 10-Q.  The delay in filing the second quarter report is related to the Company's application of certain aspects of ASC 606 in the Company's first quarter Form 10-Q.  The Company will be filing an amended Form 10-Q for the first quarter of 2018.  The Company expects to file the second quarter report and amended first quarter report within the next few days. Intrexon and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme thebaine synthase.